Cargando…
Clinical Presentation and Outcomes of Phaeochromocytomas/Paragangliomas in Neurofibromatosis Type 1
Introduction: Patients with neurofibromatosis type 1 (NF1) are at risk of developing phaeochromocytomas/paragangliomas (PHAEO/PG). Unlike in other familial PHAEO/PG syndromes, there are no published guidelines regarding screening in asymptomatic or normotensive patients with NF1. This strategy may b...
Autores principales: | Al-Sharefi, Ahmed, Javaid, Usman, Perros, Petros, Ealing, John, Truran, Peter, Nag, Sath, Kamaruddin, Shafie, Abouglila, Kamal, Cains, Fiona, Lewis, Lauren, James, Robert Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Touch Medical Media
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785954/ https://www.ncbi.nlm.nih.gov/pubmed/31616500 http://dx.doi.org/10.17925/EE.2019.15.2.95 |
Ejemplares similares
-
Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours
por: Rico, Karen, et al.
Publicado: (2021) -
Phaeochromocytomas/paragangliomas and adverse clinical outcomes in patients with Neurofibromatosis type 1
por: Al-Sharefi, A, et al.
Publicado: (2018) -
New Developments in the Treatment of Neuroendocrine Tumours – RADIANT-4, NETTER-1 and Telotristat Etiprate
por: Sbardella, Emilia, et al.
Publicado: (2016) -
Predictors of outcome in phaeochromocytomas and paragangliomas
por: Nicolas, Marlo, et al.
Publicado: (2017) -
Precision Medicine in Phaeochromocytoma and Paraganglioma
por: Winzeler, Bettina, et al.
Publicado: (2021)